Advisory Research’s Neurocrine Biosciences NBIX Stock Holding History

Advisory Research’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,417	Closed	-$297K	–	381
2018 Q3	$297K	Sell	2,417 -1,124	-32%	-$128K	﹤0.01%	344
2018 Q2	$348K	Sell	3,541 -2,041	-37%	-$183K	0.01%	336
2018 Q1	$463K	Sell	5,582 -1,585	-22%	-$134K	0.01%	315
2017 Q4	$556K	Sell	7,167 -7,808	-52%	-$533K	0.01%	321
2017 Q3	$918K	Sell	14,975 -4,830	-24%	-$255K	0.01%	318
2017 Q2	$911K	Sell	19,805 -1,963	-9%	-$95.2K	0.01%	324
2017 Q1	$943K	Sell	21,768 -22,112	-50%	-$947K	0.01%	325
2016 Q4	$1.7M	Buy	+43,880	New	+$1.99M	0.03%	227

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Advisory Research's NBIX Position: Q4 2018 in Review

Advisory Research sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 2,417 shares — an estimated $297K sold.

Advisory Research first reported a position in NBIX in Q4 2016 and held it in 8 quarters. The position peaked at $1.7M in Q4 2016. 331 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Advisory Research reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
Advisory Research sold 2,417 Neurocrine Biosciences shares in Q4 2018, an estimated $297K.
Advisory Research first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 8 quarters.
Advisory Research's Neurocrine Biosciences position peaked at $1.7M in Q4 2016.
331 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Advisory Research's 13F filing for Q4 2018, filed 13 Feb 2019.